Following the recent success of a phase 3b clinical trial for Aztreonam in cystic fibrosis (CF) patients with Burkholderia infections, Gilead Sciences, Inc., a research-based biopharmaceutical company engaged in CF drug discovery and development, completed another phase 3 clinical trial Continue reading Gilead’s AZLI Therapy For Treatment Of PALS In Cystic Fibrosis Deemed Safe, Effective In Recent Study
A once-daily inhaled antibiotic appeared to offer long-term benefits in cystic fibrosis (CF) patients with Pseudomonas aeruginosa infection, researchers said here.
In an extension of a trial that compared investigational liposomal amikacin for inhalation (Arikace) Continue reading Cystic Fibrosis: Once-A-Day Antibiotic Durable
– Data Demonstrate Positive Trends in Lung Function and Pulmonary Exacerbations –
SOUTH PLAINFIELD, N.J., May 16, 2014 /PRNewswire/ — PTC Therapeutics, Inc. PTCT -2.85% today announced that the results of a Phase 3 study of ataluren in patients with nonsense mutation Continue reading Ataluren Phase 3 Trial Results in Nonsense Mutation Cystic Fibrosis Published in The Lancet Respiratory Medicine
Gentamicin belongs to the amino glycoside class of antibiotics and is used to treat mostly gram negative bacterial infections, including severe ones like pyelonephritis, biliary sepsis, endocarditis, and cystic fibrosis among others. It is a bactericidal Continue reading Hearing Loss From Popular Cystic Fibrosis Antibiotic Could Be Treated With Vitamin Supplements
A Phase 2 clinical trial to evaluate the safety and efficacy of an
inhaled anti-MRSA antibiotic is enrolling now.
MRSA + CF
The prevalence of MRSA lung infection in cystic fibrosis (CF) patients has risen in the past decade, currently at 27% in the U.S. Recent publications indicate that chronic Continue reading Attention CF Patients With Persistent MRSA Lung Infection
Are you a CF patient with persistent MRSA lung infection? If so, you may be interested in a Phase 2 clinical trial designed to evaluate the safety and efficacy of AeroVanc (vancomycin hydrochloride inhalation powder), the first inhaled antibiotic Continue reading CF and MRSA Clinical Trial by Savara Pharmaceutical
A chemist from the University of Copenhagen recently took out a patent for a drug capable of curing bacteria of their resistance to antibiotics, according to a press release.
Jørn B. Christensen, PhD, and colleagues from the University of Southern Denmark Continue reading US patent awarded for formula to stop bacterial resistance
My friends say I am a little excessive regarding exercise. And maybe I am. But aside from clearing my head, it helps to keep my sinuses clear. It also helps me cough out any stuff percolating in my lungs. But since I am a bilateral lung transplant recipient, my lungs (thankfully) are more clear than clogged with the usual CF gunk.
The way it works, I think, is, if I bike for about 30 minutes on my stationery bike, my sinuses seem less inflamed. But what I was told by my ENT is, exercise releases many things like endorphins and epinephrine, which reduces inflammation and makes it easier to for the our think mucus to drain or dislodge from our sinus tissue. Hence it can be removed more easily. I notice this is true after I exercise and do a nasal lavage, even if the lavage is 10 hours later. The days I bike or play tennis, the crud just comes out easier. Sometimes even in chucks–gross! And if I go in there with a Q-tip, even better. You didn’t hear that last bit from me though.
There are many times I am not motivated to exercise, believe me, but I do it because I prefer having clearer sinuses to taking antibiotics several times a year for chronic infections. To take my mind off of the task at hand I watch whatever can keep me pedaling. And really, a half an hour is not so long but decent enough to get some aerobic benefits. While they are not always immediate, it helps me feel like I am doing something to prevent future illness.
What are your tips about exercise?
JERUSALEM–(BUSINESS WIRE)–Oct. 14, 2013– Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) announces today that the U.S. Food and Drug Administration has granted approval of the generic equivalent to TOBI® (Tobramycin Inhalation Solution Continue reading Teva announces FDA approval of generic TOBI in the United States
Science/AAAS | News
Fatal weakness. Pathogens such as methicillin-resistant Staphylococcus aureus (above) develop vulnerabilities as they evolve resistance to antibiotics. Choosing antibiotics that exploit these weaknesses can thwart resistant bacteria. Continue reading If Chosen Wisely, Existing Drugs Fight Resistant Bugs